- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
R&D Locations: Groton, CT
Pfizer's world-class research and development laboratories and business center in Groton makes Connecticut the largest hub of Pfizer's Worldwide Research & Development division.
Connecticut's Center for Discovery and Development Sciences is where many of the discoveries and innovations that drive the Pfizer pipeline to new potentials occur. Pfizer Connecticut sends out vital information, tools, technologies, and compounds to scientists and researchers at every level of drug discovery and development across all of Pfizer's therapeutic areas. The discoveries and developments made at the Connecticut laboratories provide teams throughout Worldwide R&D and the Pfizer Business Units with many of the key insights, data, drug targets, and compounds they need to find and develop effective new treatments to improve the health and wellness of people around the world.
Pfizer colleagues, including highly skilled research scientists, technicians, and clinicians employ the most advanced robotics, technology and data software such as:
Liquid Compound Management and Distribution
Groton houses an expansive store of small molecule compounds which is the single global facility responsible for accepting, processing, and delivering compound orders throughout Pfizer. Through a complex, streamlined operation of highly skilled staff, fully automated robotic systems and databases, Pfizer is able to fulfill requests for multiple thousands of compounds with precision and timeliness. These compounds are then directed appropriately for assessment of their therapeutic activity, ADME or toxicity characteristics, thus facilitating the progression of drug discovery and development.
Comprising the Tissue Bank and the DNA & BioFluids repository, the BioBank is Pfizer's single center of expertise to coordinate the collection, processing, storage and distribution of biosamples. The DNA & BioFluids repository receives whole blood and biofluid samples collected, with patient consent, from Pfizer clinical trials and it is the only facility in the world to house a biosample collection in a fully automated environment with both -20°C and -80°C compartments. Together these groups drive forward our understanding of disease and the safety and efficacy of the medicines we strive to deliver. They enable us to discover new biomarkers, help us to select the patients most likely to benefit from treatment and to identify new disease targets to pursue.
Our Connecticut facilities house our preclinical BioImaging Center which uses imaging techniques to further evaluate the mechanism of action, location of action, efficacy and safety of the medicines we are developing. A cyclotron is available to generate the appropriate tracers and two MRI machines, in addition to PET and CT imaging capabilities, enable us to build confidence in our lead medicines and potentially support their transition into patients.
Our Connecticut Center for Discovery and Development Sciences facilities also ensure availability of high quality reagent antibodies to support research in the drug discovery process and in the clinic and provide global support to therapeutic areas pursuing antibody and protein therapeutics with specialized molecular biology, expression, purification, and characterization technologies. Further, the staff works to formulate dosages of oral, injectable, inhalable, topical and sprayable products, perform clinical trials, perform solubility and stability studies, and streamline operations among vendors, suppliers, and other groups throughout Pfizer to allow for optimal drug discovery and development.